MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease
Status:
Terminated
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
In this study, MGCD0103, a new anticancer drug under investigation, is given three times per
week to elderly patients with previously untreated acute myelogenous leukemia/high risk
myelodysplastic syndrome or adults with relapsed/refractory disease.